Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
University of Nebraska
Barbara Ann Karmanos Cancer Institute
Fred Hutchinson Cancer Center
Medical University of Vienna